Identification of direct transcriptional targets of V600EBRAF/ MEK signalling in melanoma

Pigment Cell and Melanoma Research

Volumn 22, Issue 6, 2009, Pages 785-798

  Packer, Leisl M ^a   East, Philip ^b   Reis Filho, Jorge S ^a   Marais, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

BRAF; Kinase inhibitor; MEK; Melanoma; Microarray

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLX 4720; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 70350089250     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00618.x     Document Type: Article

References (80)

1. Bai, L. Merchant, J.L. (2007). A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett. 581, 5904 5910.
2. Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D. Kumar, R. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26, 1224 1232.
3. Bloethner, S., Snellman, E., Lorenzo Berjemo, J., Hiripi, E., Gast, A., Thirumaran, R., Wellenreuther, R., Hemminki, K. Kumar, R. (2007). Differential gene expression in melanocytic nevi with the V600E BRAF mutation. Genes Chromosomes Cancer 46, 1019 1027.
4. Bosc, D.G., Goueli, B.S. Janknecht, R. (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20, 6215 6224.
5. Braganca, J., Swingler, T., Marques, F.I., Jones, T., Eloranta, J.J., Hurst, H.C., Shioda, T. Bhattacharya, S. (2002). Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J. Biol. Chem. 277, 8559 8565.
6. Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F., Eychene, A. Mascarelli, F. (2003). Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 278, 42409 42418.
7. Chan, D.W., Liu, V.W., Tsao, G.S., Yao, K.M., Furukawa, T., Chan, K.K. Ngan, H.Y. (2008). Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29, 1742 1750.
8. Cohen, C., Zavala-Pompa, A., Sequeira, J.H., Shoji, M., Sexton, D.G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. Arbiser, J.L. (2002). Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728 3733.
9. Collisson, E.A., De, A., Suzuki, H., Gambhir, S.S. Kolodney, M.S. (2003). Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res. 63, 5669 5673.
10. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky Jr., W.E., You, M.J., Depinho, R.A., Mcmahon, M. Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544 552.
11. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
12. Dhawan, P. Richmond, A. (2002). Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72, 9 18.
13. Dhillon, A.S., Von Kriegsheim, A., Grindlay, J. Kolch, W. (2007). Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle 6, 3 7.
14. Dhomen, N., Reis-Filho, J.S., Da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294 303.
15. Dijkmans, T.F., Van Hooijdonk, L.W., Schouten, T.G., Kamphorst, J.T., Fitzsimons, C.P. Vreugdenhil, E. (2009). Identification of new nerve growth factor-responsive immediate-early genes. Brain Res. 1249, 19 33.
16. Dong, J., Phelps, R.G., Qiao, R., Yao, S., Benard, O., Ronai, Z. Aaronson, S.A. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63, 3883 3885.
17. Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J.A., Bastian, B.C., Springer, C. Marais, R. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483 9491.
18. Ekerot, M., Stavridis, M.P., Delavaine, L., Mitchell, M.P., Staples, C., Owens, D.M., Keenan, I.D., Dickinson, R.J., Storey, K.G. Keyse, S.M. (2008). Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem. J. 412, 287 298.
19. Favata, M.F., Horiuchi, K.Y., Manos, E.J. et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623 18632.
20. Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S. Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am. J. Pathol. 162, 1807 1815.
21. Furukawa, T., Fujisaki, R., Yoshida, Y., Kanai, N., Sunamura, M., Abe, T., Takeda, K., Matsuno, S. Horii, A. (2005). Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod. Pathol. 18, 1034 1042.
22. Gentleman, R.C., Carey, V.J., Bates, D.M. et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80.
23. Goodall, J., Wellbrock, C., Dexter, T.J., Roberts, K., Marais, R. Goding, C.R. (2004). The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24, 2923 2931.
24. Gray-Schopfer, V.C., Da Rocha Dias, S. Marais, R. (2005). The role of B-RAF in melanoma. Cancer Metastasis Rev. 24, 165 183.
25. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D. Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496 505.
26. Haase, M., Schott, M., Bornstein, S.R., Malendowicz, L.K., Scherbaum, W.A. Willenberg, H.S. (2007). CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J. Endocrinol. 192, 459 465.
27. Hackel, P.O., Gishizky, M. Ullrich, A. (2001). Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 382, 1649 1662.
28. Harada, S., Esch, G.L., Holgado-Madruga, M. Wong, A.J. (2001). Grb-2-associated binder-1 is involved in insulin-induced egr-1 gene expression through its phosphatidylinositol 3′-kinase binding site. DNA Cell Biol. 20, 223 229.
29. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M. Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198 5202.
30. Hoek, K.S., Schlegel, N.C., Brafford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 19, 290 302.
31. Huang Da, W., Sherman, B.T. Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 57.
32. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U. Speed, T.P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249 264.
33. Janknecht, R., Monte, D., Baert, J.L. De Launoit, Y. (1996). The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene 13, 1745 1754.
34. Johansson, P., Pavey, S. Hayward, N. (2007). Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res. 20, 216 221.
35. Karasarides, M., Chiloeches, A., Hayward, R. et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292 6298.
36. Keeton, A.B. Messina, J.L. (2005). Modulation of Elk-dependent- transcription by Gene33. J. Cell. Biochem. 94, 1190 1198.
37. Kiss-Toth, E., Bagstaff, S.M., Sung, H.Y. et al. (2004). Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J. Biol. Chem. 279, 42703 42708.
38. Kortylewski, M., Heinrich, P.C., Kauffmann, M.E., Bohm, M., Mackiewicz, A. Behrmann, I. (2001). Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem. J. 357, 297 303.
39. Kumar, R., Angelini, S., Snellman, E. Hemminki, K. (2004). BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122, 342 348.
40. Madhunapantula, S.V. Robertson, G.P. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 68, 5 8.
41. Marais, R., Light, Y., Paterson, H.F., Mason, C.S. Marshall, C.J. (1997). Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378 4383.
42. Mcmahon, S.B. Monroe, J.G. (1996). The role of early growth response gene 1 (egr-1) in regulation of the immune response. J. Leukoc. Biol. 60, 159 166.
43. Melnikova, V.O. Bar-Eli, M. (2006). Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 19, 395 405.
44. Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., Van Der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J. Peeper, D.S. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720 724.
45. Panka, D.J., Wang, W., Atkins, M.B. Mier, J.W. (2006). The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66, 1611 1619.
46. Pavey, S., Johansson, P., Packer, L. et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060 4067.
47. Pawitan, Y., Michiels, S., Koscielny, S., Gusnanto, A. Ploner, A. (2005). False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21, 3017 3024. (Pubitemid 40916427)
48. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K. Cobb, M.H. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22, 153 183.
49. Peyssonnaux, C. Eychene, A. (2001). The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93, 53 62.
50. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19 20.
51. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B. Rosen, N. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. U S A 106, 4519 4524.
52. Ramurthy, S., Subramanian, S., Aikawa, M. et al. (2008). Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem. 51, 7049 7052.
53. Reich, A., Sapir, A. Shilo, B. (1999). Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development 126, 4139 4147.
54. Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G.E. Gambacorti-Passerini, C. (2008). BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751 759.
55. Saldanha, G., Purnell, D., Fletcher, A., Potter, L., Gillies, A. Pringle, J.H. (2004). High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer 111, 705 710.
56. Salvatore, G., De Falco, V., Salerno, P., Nappi, T.C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R.M., Wilhelm, S.M. Santoro, M. (2006). BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12, 1623 1629.
57. Sasaki, A., Taketomi, T., Wakioka, T., Kato, R. Yoshimura, A. (2001). Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation. J. Biol. Chem. 276, 36804 36808.
58. Satyamoorthy, K., Li, G., Gerrero, M.R., Brose, M.S., Volpe, P., Weber, B.L., Van Belle, P., Elder, D.E. Herlyn, M. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756 759.
59. Schulze, A., Lehmann, K., Jefferies, H.B., Mcmahon, M. Downward, J. (2001). Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981 994.
60. Sebolt-Leopold, J.S., Dudley, D.T., Herrera, R. et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5, 810 816.
61. Sewing, A., Wiseman, B., Lloyd, A.C. Land, H. (1997). High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5588 5597.
62. Smalley, K.S. Flaherty, K.T. (2009). Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br. J. Cancer 100, 431 435.
63. Smith, T.G., Karlsson, M., Lunn, J.S., Eblaghie, M.C., Keenan, I.D., Farrell, E.R., Tickle, C., Storey, K.G. Keyse, S.M. (2006). Negative feedback predominates over cross-regulation to control ERK MAPK activity in response to FGF signalling in embryos. FEBS Lett. 580, 4242 4245.
64. Solit, D.B., Garraway, L.A., Pratilas, C.A. et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358 362.
65. Sumimoto, H., Hirata, K., Yamagata, S., Miyoshi, H., Miyagishi, M., Taira, K. Kawakami, Y. (2006). Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int. J. Cancer 118, 472 476.
66. Sung, H.Y., Francis, S.E., Crossman, D.C. Kiss-Toth, E. (2006). Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific. Immunol. Lett. 104, 171 177.
67. Sung, H.Y., Guan, H., Czibula, A. et al. (2007). Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. J. Biol. Chem. 282, 18379 18387.
68. Tsai, J., Lee, J.T., Wang, W. et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U S A 105, 3041 3046.
69. Tsavachidou, D., Coleman, M.L., Athanasiadis, G., Li, S., Licht, J.D., Olson, M.F. Weber, B.L. (2004). SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res. 64, 5556 5559.
70. Turjanski, A.G., Vaque, J.P. Gutkind, J.S. (2007). MAP kinases and the control of nuclear events. Oncogene 26, 3240 3253.
71. Uribe, P., Wistuba, Ii. Gonzalez, S. (2003). BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol. 25, 365 370.
72. Vial, E. Marshall, C.J. (2003). Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116, 4957 4963.
73. Wakioka, T., Sasaki, A., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K., Tsuneoka, M., Komiya, S., Baron, R. Yoshimura, A. (2001). Spred is a Sprouty-related suppressor of Ras signalling. Nature 412, 647 651.
74. Wan, P.T., Garnett, M.J., Roe, S.M. et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855 867.
75. Wellbrock, C. Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170, 703 708.
76. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C.J. Marais, R. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338 2342.
77. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T. Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734.
78. Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E. Mcmahon, M. (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5598 5611.
79. Yazdi, A.S., Palmedo, G., Flaig, M.J. et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121, 1160 1162.
80. Yokota, H., Goldring, M. Sun, H. (2003). CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear. J. Biol. Chem. 278, 47275 47280.